Is Mirum Pharmaceuticals Inc (MIRM) overvalued? · rev $336.9M
Mirum Pharmaceuticals Inc (MIRM) is a biotechnology company listed on NASDAQ.
This page asks whether Mirum Pharmaceuticals Inc (MIRM) looks expensive on cached numbers — not a short thesis.
Latest reported MIRM revenue for 2024-12-31 was $336.9M. Net income was -$87.9M. Revenue was up 80.8% from 2023-12-31 to 2024-12-31. MIRM currently screens at market cap $6.22B.
MIRM currently screens at market cap $6.22B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MIRM 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MIRM stock page for the full model, not this heading.
Not investment advice.